Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)

PURPOSE: Pre-clinical data indicate that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers. EXPERIMENTAL DESIGN: SPIRE comprised a dose escalation phase for incurable metastatic solid cancers, followed by a randomised dose expansion phase for neoadjuvant treatm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Crabb, Simon J., Danson, Sarah, Catto, James W.F., Hussain, Syed, Chan, Danna, Dunkley, Denise, Downs, Nichola, Marwood, Ellice, Day, Laura, Saunders, Geoff, Light, Michelle, Whitehead, Amy, Ellis, Deborah, Sarwar, Naveed, Enting, Deborah, Birtle, Alison, Johnson, Bernadette, Huddart, Robert, Griffiths, Gareth
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611191/
https://ncbi.nlm.nih.gov/pubmed/33472913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3946
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi